Viewing Study NCT06217393

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 1:06 AM
Ignite Modification Date: 2026-05-29 @ 8:23 AM
Study NCT ID: NCT06217393
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-01-29
First Post: 2023-11-24
Is Gene Therapy: True
Has Adverse Events: False
Brief Title: Trial of Itopride 150mg Once a Day Versus Itopride 50 mg Thrice a Day; in Patients With Functional Dyspepsia
Sponsor: Abbott
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Functional Dyspepsia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Functional Dyspepsia View
None gastrointestinal symptoms View
None gastric dysmotility View
None Bloating View
None Early satiety View
None postprandial fullness View
None upper abdominal pain View
None nausea and vomiting View
None anorexia View
None heartburn View
None chronic gastritis View